The Patients, Advocates, and Rheumatology Teams Network for Research and Service (PARTNERS) consortium was selected to receive a 2-year grant to implement a Pediatric rheumatology Learning Health System (LHS) that will work with networks in the Patient-Centered Outcomes Research Institute (PCORI) PCORnet Learning Healthcare System Collaborative.
The PARTNERS Pediatric LHS will provide support for patients with juvenile idiopathic arthritis (JIA) and their families to actively engage in care and self-management activities. JIA is a rare disease, making it difficult to study. Currently there is no cure for JIA. Recent advances in drug development have resulted in many therapies, including biologics. However, there remain many unanswered questions about how to use available therapies. While early diagnosis and initiation of treatment have proven to improve outcomes, variation exists in treatment patterns across providers, medical centers, and geographic locations.
Continue reading PARTNERS Pediatric Learning Health System: New JIA Project Focuses on Improving Outcomes for Children
We recently gave approximately $160,000 toward childhood arthritis research in the form of research grants. The grants are funded through the Childhood Arthritis and Rheumatology Research Alliance (CARRA); small grants were given to pediatric rheumatologists and fellows small grant research awards were given to third year fellowship students.
Continue reading Spring 2018 Childhood Research Grants Announced
“Why did my child get arthritis?” This parent-driven question is at the heart of Dr. Jim Jarvis’s juvenile idiopathic arthritis (JIA) Arthritis Foundation-funded project, “Interplay between genetics and epigenetics in polyarticular JIA”.
“This is less about an illness driven by inherited genes and more about how the environment affects gene expression,” explained Dr. Jarvis. “It’s been shown that only about 30 percent of the risk for developing JIA can be attributed to gene variations.”
Continue reading Researchers on the Path to a Cure – Spotlight on Dr. James Jarvis
Champion of Yes has come to mean different things to different people. To many, it means refusing to let arthritis win – to stand up, push back and say, “Enough is enough. I won’t let arthritis stop me or anyone else from living life to its fullest!”
Continue reading Winterhoff Arthritis Scholarship Goes National – Eight 2017 Recipients Announced
Dr. Rae Yeung believes in collaboration and building networks to solve problems. Her current 3-year Arthritis Foundation-funded project, “Precision Decisions to STOP JIA”, is an example of that. The goal is to develop a tool that will predict treatment response to specific drugs. Dr. Yeung’s study focuses on a group of high-risk children with polyarthritis, one of the most severe forms of childhood arthritis that affects many joints and is difficult to treat.
Continue reading Researchers on the Path to a Cure – Spotlight on Dr. Rae Yeung
The recent findings of a huge study may erase some concerns about a pain reliever that has long been saddled with a worrisome reputation: celecoxib (Celebrex). While all nonsteroidal anti-inflammatory drugs (NSAIDs) carry a warning that users have an increased risk for heart attacks and strokes, celecoxib is closely linked to two similar drugs that were taken off the market due to concerns about their cardiovascular safety. However, the new research suggests that celecoxib may not be more dangerous than other NSAIDs, and might even be safer in some important ways. Continue reading Celecoxib: Not So Hard on the Heart?
The Food and Drug Administration (FDA) has approved etanercept-szzs (brand name: Erelzi), a biosimilar form of etanercept (Enbrel), to treat rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis as well as plaque psoriasis. Earlier this year, infliximab-dyyb (Inflectra), a biosimilar version of infliximab (Remicade), became the first FDA-approved biosimilar for inflammatory types of arthritis in the U.S.
Continue reading FDA Approves Second Arthritis Biosimilar – Biosimilar Version of Drug Enbrel
Graci is 11-years-old and stands just five feet tall. But don’t let her age and size fool you. She’s wiser than most and has the stature of a superstar.
Graci has battled juvenile polyarticular arthritis for most of her life. As a member of our Advocate program, she has been very active fighting on behalf of people with arthritis.
Continue reading CBS’s Sunday Morning Features 11-year-old Arthritis Foundation Advocate, Graci Diggs
Last week more than 400 pediatric rheumatologists, researchers, fellows, patients, parents and industry representatives, along with Arthritis Foundation staff members and volunteers, came together for the 2016 Annual Scientific Meeting of CARRA, the Childhood Arthritis and Rheumatology Research Alliance. Held in Toronto, Canada, this was CARRA’s largest annual meeting to date, with participants from renowned institutions across the United States and abroad.
For nearly 70 years, the Arthritis Foundation has been committed to serving families affected by juvenile arthritis and other childhood rheumatic diseases. We’ve supported CARRA since it formed more than a decade ago, and today our partnership is stronger than ever. Both CARRA and the Arthritis Foundation are working to improve treatments and outcomes for the estimated 300,000 children in the U.S. who live with arthritis and related conditions. Together, we are creating a more unified and powerful research and advocacy community by leveraging physicians, researchers and staff from both organizations.
Continue reading Pediatric Rheumatologists, Researchers and Patients Unite in Toronto to Change the Future of Living With Childhood Arthritis
With the cost of college tuition and other academic fees constantly on the rise, getting free money to pursue a degree can be a real blessing and honor. To make educational and career goals easier to obtain, our friends at AbbVie have established the AbbVie Rheumatology Scholarship, open only to exceptional students living with one or more of four rheumatic diseases.
Applicants must submit proof of being diagnosed with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis or ankylosing spondylitis. Also required is proof of enrolling in an accredited, U.S.-based institution for the 2016-17 academic year.
Continue reading $15,000 Scholarship Opportunity for Young People With Arthritis